/

INDV

Indivior Pharmaceuticals, Inc.Pre-market

36.06+0.23 +0.64%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

35.99

Prev close

35.83

Day range

35.3736.32

52-week range

23.6742.81

Volume

6.42M2.88×

Mkt cap

4.26B

P/E ttm

12.92

Fwd P/E

7.38

EPS ttm

2.79

Div yield

0.00%

Earnings

Aug 3, 2026

From 52w high

−15.77%

Price Chart

Yahoo Finance · delayed

INDVOct 12, 2026O 36.00H 36.32L 35.37C 36.06+0.23 (+0.64%)Vol 7.47M

SMA 5036.29
SMA 20035.73

1Y change +51.64% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INDV Indivior Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.19%
1 month: +4.55%
3 months: −10.32%
6 months: +14.11%
Year to date: +0.50%
1 year: +51.64%

Valuation & ownership

Market cap: 4.26B
Enterprise value: 4.54B
P/E (ttm): 12.92
Forward P/E: 7.38
PEG ratio: —
Price / book: —
Price / sales (ttm): 3.20
EV / EBITDA: 7.89
EPS (ttm): 2.79
EPS (forward): 4.88
Beta (5y monthly): 1.18
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 118.03M
Float: 109.46M
Short % of float: 10.48%
Short ratio (days): 5.23
Held by insiders: 1.80%
Held by institutions: 102.98%
Avg volume (3m): 2.23M
50-day average: 36.29
200-day average: 35.73
52-week change: +51.64%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 51.5
vs 50-day SMA: −0.64%
vs 200-day SMA: +0.91%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 2.75%
Realised vol (20d, ann.): 25.6%
From 52-week high: −15.77%
From 52-week low: +53.12%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

49.00

+35.88% implied

Low 43.00Median 50.00High 53.00

Recommendation trend

Now4 / 0 / 0
1m ago6 / 0 / 0

Buy / hold / sell counts

DES

About Indivior Pharmaceuticals, Inc.

Yahoo Finance profile

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 827
Headquarters: North Chesterfield, VA, United States
Website: indivior.com
Officers: Mr. Joseph J. Ciaffoni CEO & Director
Mr. Ryan Preblick

SEAS

Seasonality · INDV

2014–2026 · monthly returns

Strongest month Jul +13.73%Weakest month Sep −9.54%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-1.4	-7.5	-6.8	20.7	-2.1	13.9	-2.5	-12.7	2.6	0.6			+0.5%
2025	-4.3	-22.4	3.1	20.8	11.7	14.6	37.0	20.2	-0.7	21.8	14.4	6.8	+188.7%
2024	15.5	21.5	-0.0	-18.0	4.3	-12.0	-14.7	-9.1	-22.0	-7.6	24.4	10.9	−18.6%
2023	11.6	-22.5	-10.9	11.9	-3.3	31.3	-6.6	0.0	3.7	-20.3	-7.9	-9.8	−29.8%
2022	-14.8	22.4	4.2	8.0	1.7	-10.2	1.9	-8.0	-13.5	32.4	5.9	3.4	+26.1%
2021	19.5	2.9	-4.2	22.9	1.4	-1.9	10.0	14.0	10.0	16.5	-7.4	9.9	+135.5%
2020	-4.2	6.0	13.6	5.5	26.4	28.8	69.9	-11.8	-9.3	-3.6	2.2	6.2	+181.7%
2019	10.4	-8.1	-12.4	-59.9	12.1	-5.2	25.2	11.1	-19.4	-5.6	4.1	-7.6	−61.5%
2018	2.9	-8.7	8.3	12.5	1.7	-21.2	-20.7	-12.1	-31.2	-2.1	-47.3	8.0	−75.5%
2017	2.5	18.7	-8.1	3.8	1.9	-2.9	25.0	5.9	-17.6	12.3	-3.0	13.4	+54.9%
2016	-23.5	9.1	0.0	6.6	1.2	34.2	16.8	8.3	-6.4	-0.3	5.2	-13.0	+30.5%
2015	12.0	3.2	3.8	10.7	20.9	3.2	7.2	-16.3	1.5	-7.8	-7.8	-5.9	+20.9%
2014													—

INSD

Insider Activity · INDV

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.32M shares

Sells, 6 months

73.2K shares

Net shares

+1.25M

Net change in insider shares

+141.60%

Date	Insider	Transaction	Shares	Value
Aug 26, 2026	Anderson Woodrow DOfficer	Purchase at price 35.69 per share.	1.5K	$53.53K
Aug 4, 2026	Anderson Woodrow DOfficer	Purchase at price 36.28 per share.	1.5K	$54.42K
Jul 9, 2026	Heidbreder ChristianOfficer	Sale at price 41.14 per share.	18.6K	$764.63K
Jun 21, 2026	Ciaffoni Joseph JChief Executive Officer	—	1.27M	—
Jun 10, 2026	Heidbreder ChristianOfficer	Sale at price 38.06 per share.	18.6K	$707.38K
Jun 7, 2026	Preblick RyanChief Financial Officer	Sale at price 37.70 per share.	36K	$1.36M
May 12, 2026	Ninivaggi Daniel ADirector	Stock Award(Grant) at price 0.00 per share.	6.5K	—
May 12, 2026	Kingsley Stuart ADirector	Stock Award(Grant) at price 0.00 per share.	6.5K	—
May 12, 2026	Stejbach MarkDirector	Stock Award(Grant) at price 0.00 per share.	6.5K	—
May 12, 2026	Thompson JulietDirector	Stock Award(Grant) at price 0.00 per share.	6.5K	—
May 12, 2026	Wheadon David E.Director	Stock Award(Grant) at price 0.00 per share.	10.4K	—
May 12, 2026	Ryan BarbaraDirector	Stock Award(Grant) at price 0.00 per share.	6.5K	—
May 12, 2026	Humphreys KeithDirector	Stock Award(Grant) at price 0.00 per share.	6.5K	—
Mar 12, 2026	Ryan BarbaraDirector	Purchase at price 31.08 per share.	8	$249
Mar 12, 2026	Preblick RyanChief Financial Officer	—	6.3K	—
Mar 8, 2026	Ryan BarbaraDirector	Purchase at price 32.56 per share.	31	$1.01K
Mar 5, 2026	Kingsley Stuart ADirector	Purchase at price 31.86 per share.	940	$29.95K
Mar 2, 2026	Burris Jeffrey WOfficer	—	79.9K	—
Mar 2, 2026	Heidbreder ChristianOfficer	—	101.5K	—
Mar 2, 2026	Anderson Woodrow DOfficer	—	24.3K	—

13F

Investors Holding INDV

latest 13F filings of 29 followed managers

Investors holding INDV
Investor	Value	Of portfolio	Shares	Change	Quarter
Oaktree Capital · Howard Marks	$251.4M	3.49%	6.13M	New	Q2 2026
Bridgewater Associates · Ray Dalio	$2.8M	0.01%	68.18K	+84%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

INDV

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INDV

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Indivior Pharmaceuticals, Inc.

Seasonality · INDV

Insider Activity · INDV

Congress Trades · INDV

Investors Holding INDV

Investors Holding INDV

Congress Trades · INDV

Insider Activity · INDV

Seasonality · INDV

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Indivior Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News